Armistice Capital LLC Has $80.15 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Armistice Capital LLC increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 108.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 651,626 shares of the specialty pharmaceutical company’s stock after buying an additional 338,882 shares during the quarter. Jazz Pharmaceuticals accounts for about 1.1% of Armistice Capital LLC’s portfolio, making the stock its 9th biggest holding. Armistice Capital LLC owned about 1.03% of Jazz Pharmaceuticals worth $80,150,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Polaris Capital Management LLC grew its stake in Jazz Pharmaceuticals by 2.2% in the fourth quarter. Polaris Capital Management LLC now owns 1,267,460 shares of the specialty pharmaceutical company’s stock valued at $155,898,000 after purchasing an additional 27,100 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $380,000. International Assets Investment Management LLC bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $7,201,000. Desjardins Global Asset Management Inc. bought a new position in Jazz Pharmaceuticals in the fourth quarter valued at approximately $1,943,000. Finally, Kovack Advisors Inc. grew its stake in Jazz Pharmaceuticals by 347.1% in the fourth quarter. Kovack Advisors Inc. now owns 29,971 shares of the specialty pharmaceutical company’s stock valued at $3,686,000 after purchasing an additional 23,267 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

NASDAQ:JAZZ traded up $2.70 during mid-day trading on Wednesday, hitting $107.18. 196,625 shares of the stock were exchanged, compared to its average volume of 665,697. The stock has a market capitalization of $6.76 billion, a price-to-earnings ratio of 21.54, a price-to-earnings-growth ratio of 1.62 and a beta of 0.62. The firm’s 50-day simple moving average is $110.63 and its 200 day simple moving average is $117.98. The company has a debt-to-equity ratio of 1.38, a quick ratio of 1.90 and a current ratio of 2.27. Jazz Pharmaceuticals plc has a fifty-two week low of $103.01 and a fifty-two week high of $146.70.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Wednesday, May 1st. The specialty pharmaceutical company reported $1.98 earnings per share for the quarter, missing the consensus estimate of $3.53 by ($1.55). The company had revenue of $901.98 million during the quarter, compared to analyst estimates of $938.99 million. Jazz Pharmaceuticals had a net margin of 8.61% and a return on equity of 27.86%. As a group, equities analysts anticipate that Jazz Pharmaceuticals plc will post 15.35 EPS for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 5,000 shares of Jazz Pharmaceuticals stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $109.65, for a total value of $548,250.00. Following the completion of the transaction, the executive vice president now directly owns 36,629 shares of the company’s stock, valued at approximately $4,016,369.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 4.40% of the company’s stock.

Analyst Ratings Changes

JAZZ has been the subject of a number of analyst reports. Royal Bank of Canada restated an “outperform” rating and issued a $195.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, February 29th. Cantor Fitzgerald reiterated an “overweight” rating and set a $180.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, April 10th. Stifel Nicolaus lifted their target price on Jazz Pharmaceuticals from $225.00 to $230.00 and gave the stock a “buy” rating in a research note on Friday, March 15th. Truist Financial reiterated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 20th. Finally, Barclays reduced their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Friday, May 3rd. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $190.92.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.